Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant cancer of the pancreas, with less than 5 percent of patients surviving five years after diagnosis.
UJEMI-PEARLS
Oncolytic Viruses, Bi-specific T Cell Engagers and CAR-T Cells: A Promising Triple Combination Therapy for Pancreatic Ductal Adenocarcinomas
Monday, September 28, 2020
Volume 4
Fall 2019 / Winter 2020
Oncolytic Newcastle disease virus can enhance anti-PD-1 checkpoint blockade for the treatment of muscle-invasive bladder cancer
Thursday, September 24, 2020
Volume 4
Fall 2019 / Winter 2020
Urothelial carcinoma (UC) is the most frequent malignancy of the urinary tract and the tenth most common cancer worldwide, resulting in almost 200,000 deaths every year. Muscle-invasive bladder cancer (MIBC) is an advanced stage of bladder cancer that affects 1 in 4 people diagnosed with UC.
Crossing Barriers: How JC Virus Crosses the Blood Brain Barrier and Induces Progressive Multifocal Leukoencephalopathy in Patients on Disease-Modifying Therapies.
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease caused by the John Cunningham virus (JCV).
Leishmania RNA Virus: Mere Endosymbiont or Major Player in Leishmania-Associated Disease?
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Leishmaniasis is a vector-borne disease caused by various species of Leishmania parasites. They are transmitted by the bites of infected sand flies and go on to infect host macrophages.
Bioengineering ZIKV-like Exosomes in the Treatment of Drug- Resistant Glioblastoma
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Oncolytic viruses are becoming one of the most promising avenues of therapy against a diverse range of cancers due to inherent tumour specificity. Classically, the difficulty associated with the use of viruses for cancer treatment has been how to minimize off target effects.
Salivary Exosomal microRNAs: Discovery and Potential Biomarkers for Human Papillomavirus-Associated Oral Squamous Cell Carcinoma
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Exosomes are small, membrane bound vesicles secreted by many types of cancers including oral squamous cell carcinoma (OSCC), and have been found to contain various cargo, including microRNAs (miRNAs).
The War on Arboviruses: Leveraging Co-Infection Inhibition and Endogenous Viral Elements Towards Inhibiting Arbovirus Horizontal Transmission
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Clinically significant arboviruses like dengue virus, zika virus, and chikungunya virus currently impose a major global health crisis due to their high frequency of transmission and from the lack of approved antivirals and vaccines against them.
Ebola Virus and Malaria Coinfection: How Infection with One Pathogen May Protect Against Another
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Both malaria and Ebola virus have been the centre of global health care efforts in recent years, due to the massive ongoing disease burden of malaria and the largest Ebola outbreak in history in West Africa.
MERS-CoV: Identifying Viral and Host Factors Associated with Transmission, Pathogenesis, and Treatment Development
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel betacoronavirus that is associated with a high mortality rate (~36%) and is endemic in the Middle East. Since 2012, there have been 2100 laboratory confirmed cases and 730 deaths associated with MERS-CoV in 27 countries.
A Cure for Cancer? The Therapeutic Potential of Combining Oncolytic Viruses and Chimeric Antigenic Receptor T-Cell Therapy
Wednesday, September 5, 2018
Volume 3
Fall 2017 / Winter 2018
SUMMARY Cancer continues to be a devastating diagnosis. Fortunately, active research has developed and refined two cancer therapies: oncolytic virotherapy and the novel chimeric antigen receptor (CAR) T-cell therapy.